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Abstract
 
Hyaluronan (HA), a high molecular weight glycosaminoglycan, is expressed abundantly in the
extracellular matrix and on cell surfaces. Although HA is known to bind many adhesion mole-
cules, little information has been available with respect to its direct physiological role. In this
study, we developed a novel 12-mer (GAHWQFNALTVR) peptide inhibitor of HA, termed
“Pep-1,” by using phage display technology. Pep-1 showed specific binding to soluble, immo-
bilized, and cell-associated forms of HA, and it inhibited leukocyte adhesion to HA substrates
almost completely. Systemic, local, or topical administration of Pep-1 inhibited the expression
of contact hypersensitivity responses in mice by blocking skin-directed homing of inflamma-
tory leukocytes. Pep-1 also inhibited the sensitization phase by blocking hapten-triggered mi-
gration of Langerhans cells from the epidermis. These observations document that HA plays an
essential role in “two-way” trafficking of leukocytes to and from an inflamed tissue, and thus
provide technical and conceptual bases for testing the potential efficacy of HA inhibitors (e.g.,
Pep-1) for inflammatory disorders.
Key words: glycosaminoglycan • leukocyte homing • contact hypersensitivity • Langerhans 
cell • phage display
 
Introduction
 
Extracellular matrix molecules (e.g., fibronectin, laminin,
collagens, proteoglycans, and glycosaminoglycans) bind
specific cell surface receptors via protein–protein and pro-
 
tein–carbohydrate interactions. Hyaluronan (HA),
 
1
 
 a large
glycosaminoglycan consisting of repeating disaccharide
 
units of 
 
N
 
-acetyl glucosamine and glucuronic acid, is ex-
pressed abundantly in the extracellular matrix as well as on
cell surfaces. HA has been shown to bind several different
molecules, including CD44 (1, 2), the receptor for HA-
mediated motility (RHAMM [3]), link protein (4), aggre-
can (5), versican (6), hyaluronectin (7), neurocan (8), liver
 
sinusoidal endothelial HA receptor (9), inter-
 
a
 
-trypsin in-
hibitor–related proteins (10), BEHAB (brain-enriched HA
binding; reference 11), CD38 (12), lymphatic vessel endo-
thelial HA receptor 1 (13), and white fat/bone marrow/os-
teoblast HA binding proteins (14). Conversely, CD44
binds not only HA, but also collagens (15, 16), fibronectin
(17), chondroitin sulfates (18), heparin (18), heparin sulfate
(18), and serglycins (19). Thus, although CD44 (or HA) is
generally considered to be a primary HA receptor (or a
principal CD44 ligand), HA–CD44 interaction represents
one of the multiple mechanisms by which HA and CD44
may regulate cellular activities.
Previous studies using CD44 inhibitors (e.g., anti-CD44
antibodies and fusion proteins containing extracellular do-
mains of CD44) have established the concept that CD44 is
involved in diverse cellular functions such as cell adhesion
and migration (2, 20, 21), expression of other adhesion
molecules (22, 23), leukocyte activation (24, 25), produc-
tion of cytokines and chemokines (26–28), apoptosis (29,
30), and tumor metastasis (31–33). The same inhibitors
have also exhibited potent pharmacological activities in an-
imal models of T cell–mediated inflammatory diseases (21,
34). These observations may initially appear to support the
notion that HA–CD44 interaction participates in the roll-
ing of leukocytes over endothelial cells, thus promoting
leukocyte homing (35, 36). However, it should be pointed
out that those CD44 inhibitors (which potentially interfere
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with the binding of CD44 to its multiple ligands) revealed
the function of CD44, but not the role for HA. We rea-
soned that reagents designed to block the function of HA
would provide a unique tool for studying physiological
roles of HA. Here, we report the biochemical and biologi-
cal properties of a newly developed HA inhibitor.
 
Materials and Methods
 
Animals and Cell Lines.
 
Female BALB/c mice (6–8 wk) were
purchased from The Jackson Laboratory. All animal experiments
were approved by the Institutional Review Board. The SVEC
endothelial cell, Pam 212 keratinocyte, and XS106 Langerhans
cell lines were maintained as described previously (37–40). The
BW5147 thymoma line was purchased from American Type
Culture Collection, and T cells were isolated from BALB/c mice
and from human peripheral blood by using T cell enrichment
columns (R&D Systems).
 
Isolation of HA-binding Peptides by Phage Display.
 
The M13
phage library (Ph.D.-12™ kit) expressing random 12-mer pep-
tides fused to pIII proteins with the complexity of 
 
z
 
10
 
9
 
 was pur-
chased from New England Biolabs, Inc. Falcon 35-mm tissue
culture dishes (Becton Dickinson) were incubated overnight at
4
 
8
 
C with 2.5 mg/ml of sodium HA (
 
.
 
95% pure preparation de-
rived from bacterial fermentation; Acros Organics) in distilled
water. In the fourth cycle of panning, the HA concentration was
reduced to 250 
 
m
 
g/ml. After extensive washing with PBS, the
HA-coated plates were countercoated with 1% BSA in PBS con-
taining 0.1% Tween 20 for 2 h at 37
 
8
 
C. Phage with titers of 10
 
10
 
PFU (first cycle) or 10
 
11
 
 PFU (subsequent cycles)
 
 
 
suspended in
0.01% BSA in PBS were incubated on the HA-coated plate for
30 min at room temperature with gentle rocking. Subsequently,
the plate was washed 10 times with 0.1% Tween 20 in PBS to re-
move unbound phage, then incubated for 2 h at 37
 
8
 
C with 330
U/ml hyaluronidase (HAase; Sigma-Aldrich) in enzyme buffer
(20 mM NaH
 
2
 
PO
 
4
 
, 77 mM NaCl, 0.01% BSA, pH 6.0). The
phages that were eluted by the HAase treatment were amplified in
 
Escherichia coli
 
, titrated, and then subjected to the next cycle of
panning. After the second panning against HA-coated plates, the
phages were incubated on the plate coated with 2.5 mg/ml chon-
droitin sulfate A (CSA; Sigma-Aldrich) to remove the clones that
bound nonspecifically to glycosaminoglycans. After four cycles of
positive selection over HA and an additional cycle of negative se-
lection over CSA, 19 independent phage plaques were picked
randomly, and single-stranded DNAs isolated from these clones
were sequenced using the primer 5
 
9
 
-CCCTCATAGTTAGCG-
TAACG-3
 
9
 
. Deduced amino acid sequences were then searched
for their molecular identities and homologies using advanced
BLAST search (EMBL/GenBank/DDBJ) and AA CompIdent
tool (SWISS-PROT and TrEMBL).
 
Synthesis and Labeling of Pep-1 and Other Peptides.
 
Pep-1 and
other control peptides were synthesized in house or by Research
Genetics using standard fMOC chemistry. The amidated G-G-
G-S linker sequence was included at the COOH terminus of
each peptide. Each synthetic peptide was analyzed by reverse-
phase HPLC and mass spectrometry to assure the purity and
identity. Biotinylated peptides were synthesized by the addition
of an amidated Lys residue at the COOH terminus with biotin
covalently linked to the 
 
e
 
-amine.
 
 
 
Peptide stock solutions were
prepared immediately before use by dissolution in DMSO fol-
lowed by dilution in PBS to achieve 1 or 2 mg/ml concentration
in 2% DMSO. Peptide solutions (1 mg/ml) were iodinated by a
 
3-h incubation on ice with 1 mM sulfosuccimidyl-3-(4-hydroxy-
phenyl) proprinate (Pierce Chemical Co.), followed by labeling
with 10 
 
m
 
Ci/ml of 
 
125
 
I (ICN Biomedicals) using IODO-beads
(Pierce Chemical Co.).
 
Pep-1 Binding to HA-coated Beads.
 
Uncoated paramagnetic
beads (Dynal) were labeled with 2 mg/ml HA according to the
protocol from the manufacturer, and then were countercoated
with 3% BSA in PBS overnight at 4
 
8
 
C. To test binding, 
 
125
 
I-
labeled peptides in 3% BSA in PBS were incubated with the HA-
coated beads for 1 h at 4
 
8
 
C, washed three times, and then
counted for radioactivities. HA-specific binding was determined
by subtracting the baseline cpm that bound to noncoated beads
from the cpm associated with the HA-coated beads. Specific
binding was then calculated from the specific activity (
 
z
 
3.45 
 
3
 
10
 
7
 
 cpm/
 
m
 
g) and the number of beads added to the assay.
 
Cellular Binding of Biotinylated Pep-1 and FITC-conjugated HA.
 
The SVEC endothelial cells were incubated for 30 min on ice
with biotinylated peptides (100 
 
m
 
g/ml), washed extensively,
labeled with FITC-conjugated streptavidin (Jackson ImmunoRe-
search Laboratories), and then analyzed by FACSCalibur™ (Bec-
ton Dickinson). Some samples were pretreated with 330 U/ml
HAase before incubation with peptides to assess HA specificity.
The BW5147 thymoma cells were incubated for 30 min on ice
with FITC-conjugated HA (0.4 
 
m
 
g/ml; reference 41), washed
extensively, and then analyzed by FACS
 
®
 
. In some experiments,
FITC-conjugated HA was first incubated with Pep-1 or control
peptides for 2 h at 4
 
8
 
C before the binding assay.
 
Cell Adhesion Assays.
 
HA solutions (100 
 
m
 
l/well) were added
to Amine CovaLink 96-well plates (Nunc), followed by addition
of 50 
 
m
 
l of 0.1 N HCl and 50 
 
m
 
l of 200 
 
m
 
M 1-ethyl-3-(3-dimeth-
ylaminopropyl)-carbodiimide (Pierce Chemical Co.). After over-
night incubation at room temperature, the wells were washed
three times with PBS containing 2 M NaCl and 40 
 
m
 
M MgSO
 
4
 
,
followed by two additional washes with PBS alone. The HA-
coated plates were then countercoated with 5% FCS in PBS for
2 h at 37
 
8
 
C. Cells were radiolabeled with 30 
 
m
 
Ci/ml of [
 
35
 
S]
methionine/cysteine (ICN Biomedicals) for 2 h (BW5147 cells)
or overnight (other cell types), washed extensively, and incubated
in PBS containing 5% FCS and 2 mM CaCl
 
2
 
 on the HA-coated
plates for 30 min at room temperature. After removal of nonad-
herent cells, the adherent cells were solubilized in 1% SDS and
counted for radioactivities. The percentages of adherent cells
were calculated by dividing the recovered cpm by the total cpm
added to each well. In some experiments, HA-coated wells were
pretreated with Pep-1 or control peptides in PBS containing 5%
FCS and 2 mM CaCl
 
2
 
 for 2 h at room temperature. Alternatively,
the cells were preincubated with 70 
 
m
 
g/ml of anti-CD44 mAb
KM81 (American Type Culture Collection) or isotype-matched
control IgG.
 
Langerhans Cell Migration Assay.
 
BALB/c mice received top-
ical application of 0.5% dinitrofluorobenzene (DNFB) on the
right ears and vehicle alone on the left ears. Ear skin samples
were harvested 24 h later and processed for whole mount stain-
ing for Langerhans cells as before (42). In brief, the epidermis
was separated as an intact sheet from the remaining dermis after a
20-min incubation in 0.5 M ammonium thiocyanate at 37
 
8
 
C,
fixed in acetone, and then stained with FITC-conjugated anti-IA
mAb 2G9 (BD PharMingen). Numbers of IA
 
1
 
 epidermal cells
(i.e., Langerhans cells) were counted under an Olympus BX60
fluorescence microscope (Olympus) equipped with a Sensys dig-
ital camera system (Photometrics) and Metaview software (Uni-
versal Imaging Corp.) at 
 
3
 
400 magnification in 10 different
fields per sample. 
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Contact Hypersensitivity Assays.
 
Contact hypersensitivity reac-
tions were examined as before (40). In brief, mice were sensitized
on shaved abdominal skin with 0.5% DNFB and challenged 7 d
later with 0.2% DNFB on the right ears. The left ears were chal-
lenged with vehicle alone to serve as controls. In the “double-
sensitization” experiments, mice were sensitized by topical appli-
cation of 0.5% DNFB on the left ears (or the abdomen) and
1.25% oxazolone (OX) on the abdomen (or the left ears); these
mice were challenged with 0.2% DNFB or 0.5% OX on the right
ears. To induce chronic inflammation, mice were sensitized with
0.5% DNFB on the ear skin and challenged repeatedly by the ap-
plications of 0.2% DNFB on the same site every other day (43).
The ear thickness was measured at 24 h (for OX), 48 h (for
DNFB), or every 24 h (in the chronic model) after challenge by a
third experimenter “blinded” to sample identity, using an engi-
neer’s micrometer. The ear swelling response was calculated as
the thickness of the right ear (painted with a hapten) minus the
baseline thickness of the left ear (painted with vehicle alone), ex-
cept for the double-sensitization and chronic inflammation ex-
periments, in which the thickness measured immediately before
challenge served as the baseline.
 
Pep-1 Treatment Protocols.
 
Pep-1 or control peptides were ad-
ministered into animals with three different protocols: (a) subcu-
taneous injection into ears (40 
 
m
 
g/ear/injection), (b) intravenous
injection (1 mg/animal), and (c) topical application on ears (40
 
m
 
g/ear) after removal of barrier function of stratum corneum by
soaking ear skin twice with acetone (42). Mice were treated with
one of these protocols before or after sensitization as described in
the figure legends.
 
Statistical Analyses.
 
Animal experiments were conducted
with 5–15 mice per group, and in vitro experiments were per-
formed with triplicate samples. Comparisons between two
groups were performed with a two-tailed Student’s 
 
t
 
-test, and
more than two groups were compared by analysis of variance
(ANOVA). Each experiment was repeated two to five times to
assess reproducibility.
 
Results
 
Isolation of HA-binding Peptides.
 
Although the phage dis-
play technology has been used almost exclusively to iso-
late peptide fragments that bind to polypeptide targets, we
reasoned that the same technology might be applicable to
isolate HA-binding peptides. The M13 phage library ex-
pressing random 12-mer peptides fused to the pIII minor
coat protein (with the complexity of 
 
z
 
10
 
9
 
) was incubated
on polystyrene plates that had been coated with HA and
countercoated with BSA. After removal of unbound phage,
HAase was added to the panning plates to elute only those
phage clones that had bound to HA, but not to polystyrene
surfaces or BSA. After four cycles of panning over HA-
coated plates, we isolated and sequenced 19 independent
phage clones. Strikingly, despite a theoretical complexity of
10
 
9
 
 in the starting population, an overwhelming majority
(13/19) of the isolated clones expressed an identical peptide
motif of G-A-H-W-Q-F-N-A-L-T-V-R, which was des-
ignated as “Pep-1.” We also identified two motifs that
were each displayed by two independent phage clones (T-
S-Y-G-R-P-A-L-L-P-A-A; Pep-2, and M-D-H-L-A-P-
T-F-R-P-A-I; Pep-3) and two motifs that were expressed
by single clones (T-L-R-A-I-W-P-M-W-M-S-S; Pep-4,
and I-P-L-T-A-N-Y-Q-G-D-F-T; Pep-5). None of these
peptide sequences showed significant (
 
.
 
25%) identities to
the known HA-binding domain sequences of CD44,
RHAMM, or link protein (44), or to any of the polypep-
tides currently registered in the EMBL/GenBank/DDBJ,
SWISS-PRO, and TrEMBL databases. Nor did they con-
tain a consensus motif, B(X)
 
7
 
B, known to be conserved
among the above three HA receptors, where B represents a
basic amino acid residue and X represents any nonacidic
residue (44). Moreover, none of the isolated peptides con-
tained “diagnostic” sequences that are commonly found in
peptides that bind nonspecifically to the polystyrene surface
(45; information from New England Biolabs, Inc.).
 
HA-binding Capacity of Pep-1.
 
We synthesized Pep-1
through Pep-4 to test their HA-binding capacities. As a
control, we synthesized a 12-mer peptide (S-A-T-P-A-S-
A-P-Y-P-L-A), termed the “random peptide” (RP), based
on the sequence expressed by a phage clone randomly se-
lected from the original library. We designed all the syn-
thetic peptides to include the spacer sequence G-G-G-S at
the COOH terminus to mimic the original configuration
of the peptide moieties fused to the pIII proteins and dis-
played on phage surfaces. These peptides were 
 
125
 
I labeled
and examined for binding to HA-coated beads. As shown
in Fig. 1 A, Pep-1, but not Pep-2 through Pep-4, showed
significantly higher binding to HA than did the RP con-
trol. Specificity of this binding was supported by the obser-
vations that: (a) Pep-1 bound to the HA-coated beads in a
dose-dependent manner with an apparent affinity of Kd 
 
5
 
1.65 
 
m
 
M (Fig. 1, B and C); (b) Pep-1 showed significantly
higher binding to the HA-coated beads than to the beads
coated with a control glycosaminoglycan CSA (Fig. 1 D);
(c) HAase treatment of the HA-coated beads abrogated
their Pep-1 binding capacity (Fig. 1 D); and (d) binding of
 
125
 
I-labeled Pep-1 to HA was inhibited in a dose-depen-
dent fashion by addition of “cold” Pep- 1 (Fig. 1 E).
On the other hand, we observed no saturation in terms
of the binding of 
 
125
 
I-labeled Pep-1 to HA-coated beads in
the direct binding assay (Fig. 1 B), and only partial (up to
45%) inhibition by addition of excess amounts of cold Pep-1
in the competition assay (Fig. 1 E). The inability to satu-
rate and achieve complete inhibition may first appear to
suggest nonspecificity of Pep-1 binding to HA. However,
saturation and complete inhibition are the features ex-
pected only for the binding of a ligand to a receptor that
has discrete and isolated binding sites. HA is a long, homo-
geneous polymer consisting of repeating disaccharide units
of 
 
N
 
-acetyl glucosamine and glucuronic acid, and thus
should be considered to be a lattice with nondiscrete and
overlapping binding sites. Under this circumstance, binding
of a ligand becomes entropically unfavorable for saturation
of the receptor. In other words, the lattice thermodynami-
cally resists being saturated, and thus, full saturation (and
complete inhibition) is only achievable by increasing the
free ligand concentration to a practically unattainable level
(46–48). Therefore, our results are in complete agreement
with the model in which multiple Pep-1 molecules bind to
HA in a specific and nondiscrete fashion. From the same 
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point of view, it should be emphasized that the above ap-
parent Kd value is a crude estimate based on the simplest
model of discrete binding and may not represent the abso-
lute affinity.
We next examined whether Pep-1 would also bind to
HA molecules expressed on cell surfaces. As shown in Fig.
2 A, biotinylated Pep-1 showed significantly higher bind-
ing than did the biotinylated RP control to the SVEC en-
dothelial cell line, which is known to express HA abun-
dantly on the surface (49). Importantly, this binding was
diminished significantly by HAase pretreatment of the
SVEC cells, indicating that Pep-1 bound primarily to HA
among many surface molecules (Fig. 2 B). Consistent with
 
the observations in the bead binding assays, Pep-2 through
Pep-4 showed no specific binding to the SVEC cells (Fig. 2
A). The Pam 212 keratinocyte line also showed significant
binding of biotinylated Pep-1, but not Pep-2 through Pep-
4, and this binding was abrogated by HAase treatment (data
not shown). These observations demonstrated the ability of
Pep-1 to bind not only to the HA-coated substrate, but
also to the HA molecules expressed on the surfaces of en-
dothelial cells and keratinocytes.
 
In Vitro Capacity of Pep-1 to Inhibit HA Function.
 
To
test the potential of Pep-1 to block the function of HA, we
employed the BW5147 thymoma cell line, which is known
to express CD44 abundantly and bind to HA (25). FITC-
conjugated HA bound to the BW5147 cell surfaces (Fig. 3
A), and this binding was inhibited by Pep-1 in a dose-
dependent fashion, with 
 
z
 
75% inhibition achieved at 500
 
m
 
g/ml (Fig. 3, B and C). By contrast, the RP control
showed no inhibitory effects at any tested concentrations.
The same cell line showed significant adhesion onto HA-
coated plates (Fig. 4 A), and the adhesion was blocked al-
most completely by anti-CD44 mAb (Fig. 4 B), indicating
that CD44 served as a primary adhesion receptor of HA for
this cell type. Importantly, Pep-1, but not the RP control,
Figure 1. Binding of Pep-1 to HA-coated beads. (A) The indicated
peptide was labeled with 125I and tested at 50 mg/ml for the binding to
HA-coated beads. (B) 125I-labeled Pep-1 was tested at the indicated con-
centrations for the binding to HA-coated beads. (C) Binding data from an
independent 125I–Pep-1 binding experiment were subjected to Scatchard
analysis to estimate relative affinity of Pep-1 binding to HA. (D) 125I-
labeled Pep-1 (50 mg/ml) was tested for the binding to HA- or CSA-coated
beads in the presence or absence of HAase pretreatment. (E) HA-coated
beads were first incubated with the indicated concentrations of nonlabeled
Pep-1 for 60 min, followed by an additional 60-min incubation with 125I-
labeled Pep-1 (50 mg/ml). All the data in this figure are representative of
at least three independent experiments, showing the means 6 SD from
triplicate samples. Asterisks indicate statistically significant differences (**P ,
0.01) assessed by ANOVA (A) or Student’s t test (D).
Figure 2. Binding of Pep-1 to surface HA expressed on endothelial
cells. (A) SVEC endothelial cells were harvested from the culture flask by
a 2-min exposure to 0.25% (wt/vol) trypsin/1 mM EDTA at room tem-
perature. The cells were then incubated for 30 min with biotinylated
Pep-1 through Pep-4 (100 mg/ml; closed histograms) or biotinylated RP
control (open histograms). After extensive washing, the cells were incu-
bated with FITC-conjugated streptavidin and subjected to FACS® analy-
ses. Data shown are representative of three independent experiments. (B)
SVEC cells were treated for 1 h at 378C with HAase (330 U/ml; closed
histogram) or mock treated (open histogram with broken lines) before in-
cubation with biotinylated Pep-1 (100 mg/ml) or with biotinylated RP
control (open histogram with a solid line). Data shown are representative
of three independent experiments. 
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inhibited the CD44-dependent adhesion to HA substrates
in a dose-dependent manner, with almost complete inhibi-
tion observed at 500 
 
m
 
g/ml (Fig. 4, B and C). These results
indicated the ability of Pep-1 to inhibit the function of
both soluble and immobilized forms of HA.
To determine which amino acid residue(s) in Pep-1
were critical, we tested biological activities of Ala-substi-
tuted mutants of Pep-1. Once again, the wild-type Pep-1
inhibited BW5147 cell adhesion to HA-coated plates (Fig.
4 D). This activity was maintained after Ala substitution of
the His residue at position 3, Asn residue at position 7, or
Arg residue at position 12. By contrast, Ala substitution at
position 4, 5, 6, 9, 10, or 11 abrogated the biological activ-
ity almost completely. Interestingly, the replaceable resi-
dues were all charged amino acids, whereas the irreplace-
able ones were either aliphatic or polar aliphatic amino
acids, implying that Pep-1 might bind to HA by a hydro-
phobic–hydrophobic interaction. A next question con-
cerned whether the amino acid composition would be
the sole determinant for the biological activity observed
with Pep-1. To test this question, we scrambled the Pep-1
sequence randomly and synthesized four composition-
matched, sequence-disparate peptides. None of these scram-
 
bled peptides blocked the adhesion of BW5147 cells to the
HA-coated plates, whereas almost complete inhibition was
achieved with the original Pep-1 (Fig. 4 E). These observa-
tions illustrate the uniqueness of the Pep-1 in terms of hav-
ing proper amino acid residues in the appropriate positions
for exhibiting its biological activity.
Consistent with the concept that HA–CD44 interaction
mediates the migration and homing of inflammatory leu-
kocytes (35, 36), mitogen-activated T cells from mouse
spleens and from human peripheral blood both showed sig-
nificant adhesion to the HA-coated plates, and anti–mouse
CD44 mAb KM81 markedly (75%) blocked mouse T cell
adhesion to HA (Fig. 4 F). The murine epidermal-derived
dendritic cell line (XS106), which exhibits many features of
mature Langerhans cells (39, 40), also bound significantly
to the HA-coated plates, whereas this binding was blocked
only partially by anti-CD44 mAb. The extent of inhibition
remained 
 
,
 
60% even at higher concentrations of mAb
(data not shown), suggesting that CD44 (or the epitope
recognized by our anti-CD44 mAb KM81) was one, but
not the only receptor mediating the adhesion of this cell
type to HA. Importantly, Pep-1 inhibited the adhesion of
all the tested leukocyte preparations to HA-coated plates
almost completely (90–100%), whereas the RP control
showed no significant effect. These observations validated
our subsequent use of Pep-1 to study physiological func-
tions of HA in animals.
 
In Vivo Impact of Pep-1 on Langerhans Cell Migration.
 
To
test pharmacological activities of Pep-1 in vivo, we have
chosen the skin as a target organ, because especially large
amounts of HA are present in the skin (50). Moreover,
CD44 has been shown to mediate Langerhans cell migra-
tion from the epidermis after inflammatory stimuli (51) and
skin-directed homing of pro-inflammatory leukocytes un-
der pathogenic conditions (21, 51, 52). Thus, we thought
that skin inflammation would provide a unique opportu-
nity to study the in vivo impact of Pep-1 on the “two-way
trafficking” of leukocytes from and to the inflamed tissue.
Consistent with a previous report (53), epidermal densities
of Langerhans cells were reduced significantly (
 
z
 
35%) 24 h
after topical application of a reactive hapten DNFB, reflect-
ing their migration into afferent lymphatics (Fig. 5 A). Two
local injections of Pep-1 before DNFB application pre-
vented Langerhans cell migration almost completely (
 
.
 
80%
inhibition in seven independent experiments). By contrast,
neither Pep-2 nor RP showed any significant effects. In the
absence of DNFB painting, Langerhans cell densities were
not affected by Pep-1 or other control peptides. These re-
sults documented the
 
 
 
in vivo ability of Pep-1 to inhibit
hapten-triggered Langerhans cell emigration from the epi-
dermis.
The Ala-substituted Pep-1 mutant (His
 
3
 
®
 
Ala), which
inhibited almost completely the adhesion of BW5147 cells
to the HA substrate, was found as efficient as the wild-type
Pep-1 in its capacity to prevent Langerhans cell migration.
By contrast, Ala substitution of Trp residue at position 4,
one of the irreplaceable residues of Pep-1, abrogated not
only the in vitro ability to inhibit cell adhesion, but also the
Figure 3. Pep-1 inhibits the binding of soluble HA to leukocyte sur-
faces. (A) BW5147 thymoma cells were incubated with FITC-conjugated
HA at the indicated concentrations, washed extensively, and analyzed by
FACS® for the mean fluorescence intensities (MFI). Data were plotted
linearly and evaluated with a hyperbolic fit (half saturation 5 1.4 mg/ml;
saturation 5 279.4 mg/ml). (B) FITC-conjugated HA (0.4 mg/ml) was
tested for the binding to BW5147 cells before (open histograms) or after
preincubation of FITC-HA with either Pep-1 or RP (500 mg/ml; closed
histograms). Broken lines indicate control samples incubated with PBS
alone. (C) FITC-conjugated HA (0.4 mg/ml) was incubated with the in-
dicated concentrations of Pep-1 (d) or RP (s), and then tested for the
binding to BW5147 cells. All data are representative of at least three inde-
pendent experiments.774 Hyaluronan Inhibitory Peptide, Pep-1
in vivo ability to prevent Langerhans cell migration (Fig. 5
A). In dose response experiments, Langerhans cell migra-
tion was inhibited partially by a single injection of 13.3 mg/
ear Pep-1 before DNFB application, with more prominent
inhibition achieved at 40 mg/ear (Fig. 5 B). By altering the
timing of Pep-1 administration, we found that DNFB-trig-
gered Langerhans cell migration was blocked completely
by a single injection of Pep-1 at 1 or 2 d before DNFB ap-
plication, whereas Langerhans cells began to migrate from
the epidermis when Pep-1 was administered 3 d before
DNFB painting (Fig. 5 C).
In Vivo Efficacy of Pep-1 to Inhibit Contact Hypersensitivity
Responses. Migration of hapten-pulsed Langerhans cells
to the draining lymph node (where antigen presentation
takes place) is the first event for sensitization, i.e., clonal
expansion of hapten-reactive T cells. Thus, it was of partic-
ular interest to determine the impact of Pep-1 on the sensi-
tization phase of contact hypersensitivity responses. BALB/c
mice received two local injections of Pep-1 or RP con-
trol into the left ears before sensitization; these mice were
then “double sensitized” by topical application of DNFB
onto the peptide-injected sites (left ear) and a second hap-
ten OX onto irrelevant sites (abdomen). When challenged
1 wk later with DNFB on the nontreated right ears, the
Pep-1 group showed significantly reduced swelling re-
sponses relative to the RP control group, indicating that
Pep-1 suppressed contact hypersensitivity responses at the
sensitization phase (Fig. 6 A, upper panels). On the other
hand, swelling responses to the second hapten OX were
comparable between the Pep-1 group and the RP group,
with the implication that locally administered Pep-1 did
not affect the sensitization process that took place in a dis-
tant site in the same animals. Conversely, the animals re-
ceiving Pep-1 injections and OX sensitization on the left
ears and DNFB sensitization on the abdomen showed sig-
nificantly reduced swelling responses only to OX (Fig. 6 A,
lower panels). The Pep-1 group and the RP group did not
differ significantly when they were resensitized to and re-
challenged with the same hapten, indicating that Pep-1 did
not cause long-term unresponsiveness (Fig. 6 B). In sum-
mary, contact hypersensitivity responses were suppressed
locally and temporally by local administration of Pep-1 be-
fore sensitization.
To test the impact on the elicitation phase, DNFB-sensi-
tized animals received two local injections of Pep-1 into
the right ears before DNFB challenge. As shown in Fig. 7
A (left), the Pep-1 group showed significantly reduced
swelling responses relative to the control groups receiving
RP, Pep-2, or PBS alone. Elicitation responses were also
inhibited significantly by a single intravenous injection of
Figure 4. Pep-1 inhibits CD44-depen-
dent leukocyte adhesion to HA substrates.
(A) 35S-labeled BW5147 cells were incu-
bated for 30 min at room temperature in the
plates coated with the indicated concentra-
tions of HA. The data shown are the means 6
SD of percentage binding from triplicate
samples. (B) Binding of 35S-labeled
BW5147 cells to the HA-coated plates (0.1
mg/ml) was tested after pretreatment of the
cells with 70 mg/ml of anti-CD44 mAb
(KM81) or control IgG, or after pretreat-
ment of the substrate with Pep-1 or RP
(500 mg/ml). Statistically significant differ-
ences (Student’s t test) are indicated with as-
terisks (**P , 0.01). (C) HA-coated plates
(0.1 mg/ml) were pretreated with the indi-
cated concentrations of Pep-1 (d) or RP
(s).  35S-labeled BW5147 cells were then
tested for the binding to these plates. (D)
Wild-type Pep-1, RP, and Ala-substituted
mutants of Pep-1 were tested at 500 mg/ml
for their ability to inhibit the adhesion of
35S-labeled BW5147 cells to HA-coated
plates. Asterisks indicate statistically signifi-
cant differences (**P  ,  0.01) compared
with the RP peptide control. (E) Composi-
tion-matched, sequence-disparate peptides
were synthesized by scrambling the Pep-1
sequence randomly. The original Pep-1,
RP, and scrambled peptides with the indi-
cated sequences were tested at 500 mg/ml
for their ability to inhibit the adhesion of
35S-labeled BW5147 cells to HA-coated
plates. Asterisks indicate statistically signifi-
cant differences (**P , 0.01) compared
with the RP peptide control. (F) Murine splenic T cells, human peripheral blood T cells, or murine Langerhans cell line XS106 were 35S-labeled and
tested for their adhesion to HA-coated plates in the presence or absence of the indicated pretreatment. Asterisks indicate statistically significant differences
(**P , 0.01). Data in this figure are representative of two or three independent experiments.775 Mummert et al.
Pep-1 or even by topical application of Pep-1 on the ear
skin before DNFB challenge (Fig. 7 A, middle and right).
Histological examination revealed that locally administered
Pep-1 reduced the extent of edema and the degree of leu-
kocyte infiltration compared with RP, Pep-2, or PBS con-
trols (Fig. 7 B). These observations were validated statisti-
cally by measuring the skin thickness and counting the
number of inflammatory leukocytes in the histology sec-
tions (Fig. 7 C). Thus, the expression of contact hypersen-
sitivity responses was inhibited at the elicitation phase by
systemic, local, or even topical application of Pep-1 in al-
ready sensitized animals.
To study the efficacy of Pep-1 in chronic skin inflamma-
tion, we employed a Th2-mediated chronic dermatitis
model developed by Kitagaki et al. (43). As shown in Fig. 7
D, repeated applications of DNFB on the same ears caused
progressive and remarkable swelling responses; for exam-
ple, the extent of ear swelling on day 6 was more than
threefold greater than the maximal responses observed in
the acute contact hypersensitivity model. Local injections
of Pep-1 immediately before and during DNFB applica-
tions diminished the swelling responses significantly at each
time point tested compared with the RP control. These
observations implied that Pep-1 might be applicable for the
treatment of acute as well as chronic inflammatory skin dis-
orders. With respect to the relative safety, none of the mice
(. 500 in total) that had received Pep-1 treatments in vari-
ous protocols died during the experimental periods of 1–6
wk. Moreover, none of the three BALB/c mice that had
received three weekly intravenous injections of Pep-1 (1
mg/injection/animal) developed any apparent adverse ef-
fects during the 3-mo follow-up period in terms of changes
in body weight and serum levels of aspartate aminotrans-
ferase, alanine aminotransferase, g-glutamyl transpeptidase,
and total bilirubin (data not shown). Nor did they develop
detectable humoral immune responses to Pep-1 (tested by
ELISA) or cellular responses (tested by proliferative re-
Figure 5. Impact of Pep-1 on hapten-triggered Langerhans cell migra-
tion. (A) BALB/c mice received two subcutaneous injections (40 mg/ear/
injection) of the indicated peptides in both ears 24 and 1 h before topical
application of 0.5% DNFB (right ears, black bars) or vehicle alone (left
ears, white bars). Ear skin samples were harvested 24 h after DNFB paint-
ing, and were examined for the surface densities of IA1 epidermal
Langerhans cells. Data shown are the means 6 SEM (n 5 5), representa-
tive of three independent experiments. Statistically significant differences
are indicated with asterisks (**P , 0.01; Student’s t test). (B) BALB/c
mice received a single subcutaneous injection (40 mg/injection) of Pep-1
at the indicated concentrations 24 h before DNFB application. Data
shown are the means 6 SEM (n 5 10) of percentage of Langerhans cell
emigration at 24 h after DNFB application, i.e., the extent of DNFB-
induced reduction in Langerhans cell density as calculated by the following
formula: [(Langerhans cell number in vehicle painted ear 2 Langerhans
cell number in DNFB painted ear)/Langerhans cell number in vehicle
painted ear] 3 100. Statistically significant differences compared with the
PBS alone group (Pep-1 dose 5 0 mg/ear) are indicated with asterisks (*P ,
0.05; **P , 0.01). (C) Pep-1 (40 mg/ear) or PBS alone was injected
subcutaneously into both ears at 3, 2, or 1 d before topical application of
0.5% DNFB (right ears, black bars) or vehicle alone (left ears, white bars).
Data shown are the means 6 SEM (n 5 5) of Langerhans cell densities at
24 h after DNFB application. Statistically significant differences are indi-
cated with asterisks (**P , 0.01).
Figure 6. Impact of Pep-1 on the sensitization phase of contact hyper-
sensitivity responses. (A) BALB/c mice received subcutaneous injections
of Pep-1 or RP (40 mg/ear/injection) 24 and 1 h before sensitization on
the left ears. The same mice were double sensitized by topical application
of 0.5% DNFB and 1.25% OX on the indicated skin sites (either left ears
or abdominal skin) and challenged 7 d later on the right ears with 0.2%
DNFB or 0.5% OX as indicated. The data are representative of two inde-
pendent experiments, showing the means 6 SEM (n 5 10) of ear swell-
ing responses at 24 h for OX and 48 h for DNFB, when maximal re-
sponses were observed for each hapten. Asterisks indicate statistically
significant differences (*P , 0.05; **P , 0.01) assessed by Student’s t test.
(B) The mice that had received Pep-1 or RP injections and DNFB sensi-
tization on the left ears (shown in A; day 0) were resensitized by topical
application of 0.5% DNFB on day 7 and rechallenged with 0.2% DNFB
on day 14. The results shown are the means 6 SEM (n 5 10) of the ear
swelling responses. Statistically significant differences are indicated with
asterisks (**P , 0.01).776 Hyaluronan Inhibitory Peptide, Pep-1
sponses of splenic T cells to Pep-1; data not shown). These
results suggested that pharmacological doses of Pep-1 could
be administered repeatedly into living animals without
causing apparent acute side effects.
Discussion
By using the phage display technology, we have isolated
a 12-mer peptide that binds to soluble, immobilized, and
cell-associated forms of HA and inhibits the function of
HA. To recapitulate the essence of our findings, Pep-1
blocked (a) in vitro adhesion of the BW5147 thymoma
line, XS106 Langerhans cell line, and murine and human T
cells to HA-coated plates; (b) hapten-triggered migration of
Langerhans cells from the epidermis; (c) contact hypersen-
sitivity responses at sensitization and elicitation phases; and
(d) chronic skin inflammation induced by repeated hapten
applications.
Langerhans cells reside normally in the epidermis, being
surrounded by keratinocytes, and they migrate to draining
lymph nodes in response to inflammatory stimuli. Ho-
mophilic interaction of E-cadherin, which is expressed by
both populations, is thought to mediate the retention of
Langerhans cells within the epidermis (54), and a6 integrins
appear to mediate Langerhans cell migration through the
dermoepidermal junction (53). Our results now document
a critical role played by HA in their migration out of the
epidermis. In this regard, other investigators have reported
that (a) HA is expressed abundantly on keratinocyte sur-
faces (55); (b) CD44 expression by Langerhans cells is up-
regulated by inflammatory stimuli in vitro (56); (c) Langer-
hans cells begin to express CD44v4, v5, v6, and v9 isoforms
in vivo after hapten painting (51); and (d) anti-CD44v6
mAb blocks Langerhans cell emigration in the skin organ
culture system (51). Thus, it is conceivable that Pep-1 pre-
vented Langerhans cell migration by interfering with mo-
lecular interaction between HA (expressed on keratinocytes
and in the dermal matrix) and specific CD44 isoforms (ex-
pressed on activated Langerhans cells). We have also ob-
served that Pep-1 inhibits contact hypersensitivity responses
at both sensitization and elicitation phases. In this regard,
other investigators have reported that (a) HA expression on
endothelial cells is upregulated by inflammatory stimuli
(57); (b) skin-infiltrating T cells in inflammatory diseases se-
lectively express CD44v10 and CD44v3 isoforms (52); and
(c) anti-CD44 mAb reduces the extent of edema and leu-
kocyte infiltration of skin, thereby inhibiting the expression
of contact hypersensitivity responses (21, 51). Thus, it is
likely that Pep-1 prevents skin inflammation by blocking
the interaction between HA (expressed on endothelial cells
and in the extracellular matrix) and specific CD44 isoforms
(expressed on skin-homing leukocytes). In summary, by us-
ing a specific inhibitor of HA, we have identified HA to
function as a primary adhesive substrate for CD44-medi-
ated migration of Langerhans cells and inflammatory leuko-
cytes from and to the inflamed skin, respectively.
Pep-1 differs from conventional CD44 inhibitors (e.g.,
anti-CD44 mAb and CD44-Ig fusion proteins) in many re-
Figure 7. Impact of Pep-1 on the expression of contact hypersensitivity
responses. (A) BALB/c mice were sensitized with 0.5% DNFB on ab-
dominal skin and challenged 7 d later with 0.2% DNFB on the right ears
and vehicle alone on the left ears. These mice received the following: (a)
two subcutaneous injections (40 mg/ear/injection) of the indicated pep-
tides into both ears 24 and 1 h before challenge (n 5 5); (b) a single intra-
venous injection (1 mg/animal) at 1 h before challenge (n 5 10); or (c) a
single topical application (40 mg/ear) at 1 h before challenge (n 5 10).
The data are representative of two independent experiments, showing the
means 6 SEM of the ear swelling responses at 48 h. Statistically significant
differences (ANOVA for the subcutaneous injection protocol and Stu-
dent’s t test for other protocols) are indicated with asterisks (*P , 0.05;
**P , 0.01). (B) Ear skin samples harvested from the animals receiving the
subcutaneous injections of Pep-1 or RP (left columns in A) were pro-
cessed for hematoxylin and eosin staining. Data shown are the representa-
tive fields (original magnification: 3100). (C) Histological samples (n 5
10) were examined by a third individual for the ear thickness and the
number of skin-infiltrating leukocytes under a microscope. Asterisks indi-
cate statistically significant differences (**P , 0.01) assessed by ANOVA.
(D) BALB/c mice were painted on both ears with 0.5% DNFB on day 0
and with 0.2% DNFB on days 2 and 4 (as indicated by closed triangles).
Pep-1 (d) or RP (s) (40 mg/ear/injection) was injected locally in the left
or right ears of the same animals, respectively, on days 0, 1, 3, and 5 (as
indicated by ,). The data shown are representative of two independent
experiments, showing the means 6 SEM (n 5 15) of ear swelling re-
sponses. Statistically significant differences between the Pep-1 group and
the RP group are indicated with asterisks (**P , 0.01; Student’s t test).777 Mummert et al.
spects. First, they differ in target specificity. Both may be
equally effective in blocking chemical HA–CD44 interac-
tion by itself, as has been observed for CD44-dependent
adhesion of BW5147 cells and T cells to HA-coated plates.
On the other hand, Pep-1 was more efficient than anti-
CD44 mAb in blocking the adhesion of XS106 cells to
HA-coated plates, perhaps reflecting the fact that CD44 is
one of the multiple HA receptors. Similar observations
have been reported by other investigators. For example, al-
though HA stimulated macrophages to elaborate IL-1b and
IL-6, anti-CD44 mAb blocked only IL-1b secretion (26).
Likewise, antibodies against RHAMM (a second cell sur-
face receptor of HA) but not against CD44 inhibited HA-
mediated locomotion of ras-transformed fibroblasts, al-
though they expressed both RHAMM and CD44 (58).
Thus, Pep-1 represents an entirely new class of inhibitors
designed to block the function of HA (instead of its recep-
tor). Secondly, CD44 represents a family of many different
isoforms resulting from alternative splicing and posttransla-
tional modifications (including glycosylation, phosphoryla-
tion, sulfation, and receptor clustering; references 49, 59–
62), whereas HA is a simple glycosaminoglycan consisting
of repeating disaccharide units, thereby providing a more
universally accessible target for inhibitors. In fact, Pep-1
bound to and inhibited the function of all tested forms of
HA molecules. Finally, the molecular size (a 12-mer pep-
tide) of Pep-1 may be an advantage over conventional
CD44 inhibitors (antibodies and fusion proteins); Pep-1,
indeed, exhibited significant pharmacological activities
even after topical application.
Preclinical efficacies have been documented for CD44
inhibitors in many inflammatory disease models, such as al-
lergic contact dermatitis (21, 51), collagen-induced arthritis
(34), autoimmune type I diabetes (63), experimental au-
toimmune encephalomyelitis (64), and allogeneic skin graft
rejection (65). Moreover, these inhibitors prevented tumor
metastasis efficiently (31–33), reflecting the fact that CD44
not only mediates the adhesion and migration of tumor
cells, but also regulates their growth (32), differentiation
(66), apoptosis (67), expression of other adhesion molecules
(68), and metalloproteinase activity (69). We believe that
Pep-1 will provide a unique opportunity to study potential
roles of HA in the above inflammatory diseases and tumor
metastasis. Studies are in progress in our laboratory to de-
termine the impact of Pep-1 on skin graft rejection and ex-
perimental lung metastasis of B16-F10 melanoma cells.
A striking observation from a chemical standpoint was
that an overwhelming majority of the peptides isolated by
phage display encoded an identical amino acid sequence
(i.e., Pep-1). This documents an exceptionally high effi-
ciency of our panning protocol, most likely owing to the
elution step with HAase treatment. We believe that this is
the first demonstration that phage display technology can be
used to isolate peptides that bind to a given carbohydrate
molecule. Even more strikingly, Pep-1 lost its biological ac-
tivity by Ala substitution of any single residue, except for
His3, Asn7, or Arg12 residue. Although the structural basis
for Pep-1 binding to HA is presently unknown, we specu-
late, based on the binding profile of Pep-1 mutants and the
known secondary and tertiary structures of HA (70, 71),
that hydrophobic and/or polar aliphatic residues of Pep-1
may function as primary binding sites for polar, hydropho-
bic, or formally charged groups on HA. We anticipate that
Pep-1 and its mutants will provide unique tools for studying
the physical and chemical interaction of HA to its ligands.
Such analyses may, in turn, lead to the development of new
Pep-1 derivatives with improved affinities to HA.
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